Pharmaceutical Sciences and Health Technologies IV.
Torma Lúcia
PEWB37
ELTE Analitikai Kémiai Tanszék
06 20 508 71 59
lucatorma98@gmail.com
Development of Daunorubicin-loaded Bovine Serum Albumin Nanoparticles
Lúcia Torma1
1: ELTE Analitikai Kémiai Tanszék
Szóbeli
Pharmaceutical Sciences and Health Technologies IV.
Hungarian
Pharmaceutical Sciences and Health Technologies
Introduction: Daunorubicin (DAU) is an anthracycline agent with an antitumour effect and is used in the treatment of different types of leukaemias. It is important to highlight the cardiotoxic properties of DAU, because this side effect can make the therapeutic use of it questionable. Albumin based nanoparticles are promising drug delivery systems (DDSs). Incorporating cytostatic agents into Bovine Serum Albumin Nanoparticles (BSA-NPs), their toxic properties can be reduced, the pharmacokinetic profile of drugs can be optimised and provide the opportunity to overcome multidrug resistance.
Aims: Our aims were to prepare DAU-incorporated BSA-NPs following the desolvation process (1); characterize the produced particles (2); optimize the preparation parameters (3); and examine the in vitro cytotoxic activity of prepared nanoparticles (4).
Methods: The general characterization of nanoparticles was determined by dynamic light scattering (DLS) and morphological investigation was performed on a Transmission Electron Microscope (TEM). The DAU-content of NPs was measured by a spectrofluorimetric calibration method. In vitro cytotoxic experiments were carried out using 4 different cell lines, and IC50 values of free drug and NPs treatment were determined by PrestoBlue cell viability assay.
Results: Different preparation parameters can influence the characteristics and therefore the cytotoxic properties of prepared nanoparticles. NPs prepared with the most ideal preparation parameters can be characterised as having a particle size of 180-200 nm, and an Encapsulation Efficiency (EE) of 65-70 %. All of the NPs showed cytotoxic effects on the tested cell lines. P388 cell line showed efficient cellular uptake of DAU and DAU-containing NPs after overnight incubation, and NPs could be characterised by sustained release in the tested media at 37 °C. NPs proved to be stable at 4 °C in different storage solutions for 8 weeks.
Based on these results, a standard protocol for the preparation of DAU-loaded BSA nanoparticles was elaborated. Furthermore, DAU-NPs were found to be able to reduce drug resistance.
Conclusion: Our findings provide the opportunity for further study, for instance testing the in vivo effect of NPs, or applying NPs containing daunorubicin and cytarabine in combinations in order to implement their synergistic effect.
Semmelweis University
Dr. Szoboszlai Norbert
I give consent to the publication of my abstract on the website of the congress.
in doctoral studies after complex exam (PhD)
Szabad
elfogadva
szóbeli
nem hagyta jóvá
9113
16:45
17:00